The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic significance of PIK3CA mutation in patients with muscle-invasive urothelial carcinoma (UC).
 
Vaibhav G. Patel
No Relationships to Disclose
 
Russell Bailey McBride
No Relationships to Disclose
 
Ana Collazo Lorduy
No Relationships to Disclose
 
Mireia Castillo-Martin
No Relationships to Disclose
 
Eugene K. Cha
No Relationships to Disclose
 
Michael F. Berger
Consulting or Advisory Role - Cancer Genetics; Sequenom
 
Li Wang
No Relationships to Disclose
 
William K. Oh
No Relationships to Disclose
 
Jun Zhu
No Relationships to Disclose
 
Carlos Cordon-Cardo
No Relationships to Disclose
 
David B. Solit
Honoraria - Loxo; Novartis; Pfizer
Consulting or Advisory Role - Loxo; Pfizer
 
John Sfakianos
No Relationships to Disclose
 
Matt D. Galsky
Stock and Other Ownership Interests - Dual Therapeutics
Consulting or Advisory Role - Astellas Pharma; BioMotiv; Dendreon; Genentech; GlaxoSmithKline; Janssen; Lilly; Merck
Research Funding - Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
Travel, Accommodations, Expenses - Astellas Pharma; BioMotiv; Dendreon; Merck